Among female patients with CML, fertility preservation with ovarian stimulation can be challenging if patients require continuation of TKIs until HSCT.
Some patients diagnosed with HP or AP have a significantly increased risk of developing pancreatic cancer.
There is no evidence that women at high risk of breast cancer, such as those who harbor BRCA1 or BRCA2 mutations, should avoid hormonal contraception.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
The combination may be an attractive option for some, but further research is needed to target the therapy effectively to particular patients.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Does Immune Checkpoint Inhibition Have A Dark Side?
- Do Oral Contraceptives Actually Increase Breast Cancer Risk?
- Rituximab Plus Bendamustine: Superior to R-CHOP for Grade 3A Follicular Lymphoma
- Encorafenib/Binimetinib Combination Shows Promise for Advanced Melanoma
- BMI, Age, and Treatment Response May Predict for Survival in Patients With Lung Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Extensive Intraoperative Peritoneal Lavage May Not Improve OS in Gastric Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer
- Could Switching to Interferon Avoid an Abnormal Ovarian Response in CML?